Mechanism of action. Apixaban selectively inhibits factor Xa in its free and bound forms, independant of antithrombin III Label. Apixaban also inhibits prothrominase Label. These effects prevent the formation of a thrombus Label.

2024年2月22日 · Mechanism of Action. The clotting cascade of apixaban encompasses a complex process comprising multiple factors operating in 3 distinct phases—initiation, propagation, and fibrin formation.

Mode of Action. Apixaban is a potent, direct, oral, reversible, and highly selective inhibitor of FXa (inhibitory constant = 0.08 nM [0.037 ng/mL] at 25 °C) [12, 13] that does not require antithrombin III for antithrombotic activity . Apixaban inhibits free and clot-bound FXa, as well as prothrombinase activity, which inhibits clot growth . By ...

Apixaban, sold under the brand name Eliquis, is an anticoagulant medication used to treat and prevent blood clots and to prevent stroke in people with nonvalvular atrial fibrillation through directly inhibiting factor Xa.

Apixaban: General aspects and mechanism of action. Apixaban is a reversible, direct and highly selective inhibitor of factor Xa. It has been extensively investigated in pre- clinical studies for the prevention of arterial and venous thrombosis.

2020年2月17日 · Inhibits platelet activation and fibrin clot formation via direct, selective and reversible inhibition of free and clot-bound factor Xa (FXa). FXa, as part of the prothrombinase complex consisting also of factor Va, calcium ions, and phospholipid, catalyzes the conversion of prothrombin to thrombin.

Apixaban is an oral, direct factor Xa inhibitor that inhibits both free and clot-bound factor Xa, and has been approved for clinical use in several thromboembolic disorders, including reduction of stroke risk in non-valvular atrial fibrillation, thromboprophylaxis following hip or knee replacement surgery, the treatment of deep vein thrombosis o...

Mechanism of Action, Metabolism, and Pharmacokinetic Profile Apixaban is an orally active small molecule reversible inhibitor of Factor Xa 3 , 4 (FXa), thus inhibiting thrombin and trypsin. It inhibits both free FXa and FXa bound within the prothrombinase complex or …

2023年7月20日 · Mechanism of action. Apixaban is a potent, direct, oral, reversible, and highly selective inhibitor of FXa (inhibitory constant = 0.08 nM [0.037 ng/mL] at 25°C) that does not require antithrombin III for antithrombotic activity. Apixaban inhibits free and clot-bound FXa, as well as prothrombinase activity, which inhibits clot growth.

2014年5月10日 · Mechanism Of Action. Apixaban is a selective inhibitor of FXa. It does not require antithrombin III for antithrombotic activity. Apixaban inhibits free and clot-bound FXa, and prothrombinase activity. Apixaban has no direct effect on platelet aggregation, but indirectly inhibits platelet aggregation induced by thrombin.